Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413
Status:
Enrolling by invitation
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
The study should evaluate the biological distribution of [99mTc]Tc-BQ0413 in patients with
prostate cancer.
The primary objective are:
1. To assess the distribution of [99mTc]Tc- BQ0413 in normal tissues and tumors at
different time intervals.
2. To evaluate dosimetry of [99mTc]Tc- BQ0413.
3. To study the safety and tolerability of the drug [99mTc]Tc- BQ0413 after a single
injection in a diagnostic dosage.
The secondary objective are:
1. To compare the obtained [99mTc]Tc- BQ0413 SPECT imaging results with the data of CT and/or
MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer
patients.
Phase:
Phase 1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences